United States Patent 9,949,990 (Celecoxib Reduced-Dose Fast-Release Oral Compositions): Claim Scope and US Patent Landscape

US Patent 9,949,990 is directed to reduced-dose celecoxib oral liquid/capsule compositions that demonstrate fast celecoxib release in simulated gastric conditions and, for certain claims, fast pharmacokinetics under fasting conditions. The claim set is structured around (i) percentage-in-media release thresholds using USP Apparatus Type 2 with defined dissolution medium and conditions, (ii) dose reductions vs “conventional celecoxib in 400 mg oral capsules,” and (iii) formulation composition ranges (solubilizer, medium chain glycerides, solvent) plus downstream method-of-use and PK claims (AUC cutoffs and Tlag limits).

The practical implication for freedom-to-operate (FTO) and generic entry risk is that any oral reduced-dose celecoxib product that meets the same dissolution thresholds (70% at 10 minutes and/or 80% at 15 minutes in 0.01N HCl + 0.5% SLS under USP<724>-like conditions) and uses broadly similar formulation classes (solubilizers, medium chain glycerides, and solvents) is exposed to direct infringement theories, even if the product is positioned as a dose-strength variation.

What does US 9,949,990 claim cover for reduced-dose celecoxib oral compositions?

Core coverage (composition claims 1, 13, 19, 25)

Drug: celecoxib.
Dosage form: “oral pharmaceutical composition,” with claim 9 expressly covering solution/suspension/emulsion/liquid mixture.
Dose concept:
- Claim 1 uses a reduced dose defined by relationship to “conventional celecoxib in 400 mg oral capsules.”
- Claims 13/19/25 lock to specific reduced dose strengths: 240 mg, 180 mg, 120 mg.
Dissolution/release requirement:
- Using 900 mL of 0.01N HCl with 0.5% sodium lauryl sulfate.
- USP Type 2 apparatus with sinkers at 50 rpm and 37°C.
- Passing one or both release tests:
  - (a) releases ≥ about 70% of celecoxib at 10 minutes, or
  - (b) releases ≥ about 80% at 15 minutes.

Feeding mechanism of infringement

The novelty and limiting feature is the combination of reduced celecoxib dose plus fast dissolution kinetics in the specified medium/apparatus settings.
This structure narrows the estate versus broad “reduced-dose celecoxib” claims that lack a defined release profile.

Dose reduction spectrum (dependent claims 2–5)

Claim 1 is broadened by dependent claims that define incremental reduction milestones vs conventional 400 mg celecoxib capsules:

Claim 2: at least 20% less
Claim 3: at least 40% less
Claim 4: at least 55% less
Claim 5: at least 70% less

These create multiple “entry points” for infringement depending on how a product qualifies as “reduced dose.”

Formulation-class limitations (dependent claims 6–8; and similarly 14–16; 20–22; 26–28)

All formulation-dependent versions follow the same architecture:

Solubilizer: 10% to 70% by weight
Medium chain glyceride: 5% to 75% by weight
Solvent: 20% to 80% by weight

Claim construction effect

Even if the invention is implemented with different excipient identities, infringement risk persists if the accused product uses formulation components that fall within these functional composition classes and weight ranges.

What release and dissolution test conditions define infringement risk?

Specified dissolution system

Medium: 0.01N HCl + 0.5% sodium lauryl sulfate
Volume: 900 mL
Apparatus: USP Type 2 with sinkers
Speed: 50 rpm
Temperature: 37°C
Acceptance thresholds:
- ≥70% at 10 minutes, and/or
- ≥80% at 15 minutes

Why this matters

Any challenge to infringement typically focuses on whether an accused product meets the same timepoint thresholds under the same apparatus and medium. Because the claim uses explicit test parameters, product characterization against those exact settings becomes decisive for viability of an infringement finding.

How do the 120 mg, 180 mg, and 240 mg versions change claim scope?

Strength-specific claims

Claim 25: 120 mg reduced dose plus the same dissolution thresholds.
Claim 19: 180 mg reduced dose plus the same dissolution thresholds.
Claim 13: 240 mg reduced dose plus the same dissolution thresholds.

Practical effect

Strength-specific claims reduce ambiguity in “conventional 400 mg” comparisons.
If a competitor targets one of these strengths, the patent exposure shifts from a relative “reduction vs 400 mg” analysis to a direct numeric element.

What method-of-use rights does US 9,949,990 include for pain?

General method-of-use (claims 11, 17, 23, 29)

“Administering the composition” to a human subject for treating or ameliorating pain.

Pain category enumeration (claim 12) The list spans acute pain, migraine pain, cluster headache, neuropathic pain, post-operative pain, chronic lower back pain, dental pain, opioid-resistant pain, visceral pain, surgical pain, pain during labor and delivery, burns/sunburn pain, post-partum pain, angina pain, genitourinary tract-related pain, cystitis pain, arthritis pain, osteoarthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, and primary dysmenorrhea pain.

How this expands enforcement

The broadness is not limited to one indication. Any analgesic positioning within the listed categories can support method-of-use infringement theories if the composition claims are met.

What pharmacokinetic (PK) performance claims are covered, and what do they require?

Fasted-state PK claim structure (claims 18, 24, 30) For each locked dose strength (present as claim 13, 19, 25 bases), the patent asserts a PK profile requirement under fasting oral administration.

Thresholds include (selectively, “at least one of the following”):

AUC(0–15 min) ≥ 10 ng·h/mL
AUC(0–30 min) ≥ 80 ng·h/mL
AUC(0–1 hr) ≥ 400 ng·h/mL
AUC(0–2 hr) ≥ 1000 ng·h/mL
AUC(0–t) ≥ 2000 ng·h/mL
AUC(0–∞) ≥ 2000 ng·h/mL
Tlag ≤ 8 minutes

Claim consequence

PK claims can be used as secondary infringement hooks even when dissolution testing arguments differ, depending on how courts interpret the relationship between the composition requirements and PK thresholds in practice.

Design-around pressure

A generic can attempt to avoid infringement by targeting failure of either the dissolution criteria or the PK criteria, but the claim text shows either pathway can be enough to meet different independent elements depending on which claims are asserted.

How strong is the claim “center of gravity” for enforcement?

Most enforceable elements

Explicit dissolution acceptance criteria under a specific medium and apparatus.
Dose reduction definition either by percentage vs “conventional 400 mg oral capsules” or by specific mg values.
Formulation class and weight ranges for solubilizer, medium chain glycerides, and solvent.
Downstream human pain treatment methods that are broad by indication.

Weaker points (in practice)

Breadth of pain categories does not change the need to prove the product meets composition and/or PK elements.
If competitors use different excipient classes, they may argue outside the “solubilizer/medium chain glyceride/solvent” category boundaries. However, because the claims use weight ranges rather than named excipients, categorical design-arounds may be limited.

What other US patents commonly overlap with celecoxib fast-release or low-dose celecoxib products?

Within celecoxib exclusivity and generic landscapes, overlap usually comes from three buckets:

celecoxib polymorph/form solid-state patents (if the dosage form is solid and specific forms are claimed),
formulation and delivery-system patents (solubilization, lipid vehicles, microemulsions, self-emulsifying systems, surfactant systems, and liquid-fill technologies), and
method-of-use patents for analgesia endpoints, specific subpopulations, or dosing regimens.

For US 9,949,990 specifically, its distinguishing features are the fast dissolution in HCl/SLS and reduced celecoxib dose plus specific formulation component ranges.

Risk mapping for a competitor

Products that merely reduce dose (e.g., 100 mg/200 mg tablets or capsules) without hitting the dissolution thresholds and formulation classes are less likely to fall inside the core claims.
Products that use lipid/surfactant/solvent enabling fast release are the highest-risk segment, especially liquid-filled or self-emulsifying formats.

What generic entry risks exist for reduced-dose celecoxib under US patent 9,949,990?

Direct infringement risk scenario

If an ANDA or 505(j) product is therapeutically equivalent to a reference-listed product and uses:
- reduced dose strength within 120/180/240 mg or qualifies as ≥20%/40%/55%/70% reduction versus a conventional 400 mg capsule benchmark, and
- meets or exceeds the specified dissolution thresholds at 10/15 minutes in 0.01N HCl + 0.5% SLS using USP Type 2 sinkers at 50 rpm/37°C,
- with solubilizer/medium chain glyceride/solvent weight ranges in the claimed bands, then infringement exposure is substantial.

PK-claim risk scenario

If product bioequivalence results show fasting AUC and Tlag metrics meeting claim 18/24/30 cutoffs, the PK hooks can intensify litigation leverage.

Design-around pathways

Miss dissolution acceptance thresholds by altering release profile in the specified medium/conditions.
Use formulation systems outside the claimed class/range boundaries (solubilizer, medium chain glycerides, solvent).
Attempt to lower AUC(0-15/30/60) or raise Tlag above 8 minutes in fasting dosing studies. This is fact-specific and depends on formulation and dissolution behavior.

What is the Orange Book status likely to look like for products tied to this patent?

The patent’s claims track a formulation and performance profile rather than a pure strength-only change, so Orange Book risk typically involves:

Drug product listings that correspond to the reduced-dose, fast-release celecoxib dosage forms (including liquid dosage forms if referenced in the listing).
Multiple patents in the same listing family may cover different aspects: composition, dissolution, PK, and method of use.

Because this analysis is confined to the claim text provided for US 9,949,990 and does not include Orange Book listing identifiers, no listing-specific status can be asserted here.

How does US 9,949,990 compare with typical celecoxib “slow-release/controlled-release” patent strategies?

US 9,949,990 is positioned opposite controlled-release paradigms:

It demands fast release (≥70% in 10 minutes or ≥80% in 15 minutes) under harsh gastric-like conditions (HCl + SLS).
This aligns with solubilized or lipid-enabled delivery systems intended to increase early exposure (Tlag ≤8 minutes and early AUC cutoffs).

A competitor using delayed release (gastroretentive or enteric) may naturally avoid these fast-release thresholds but must still address whether the claims are met in the specific dissolution setup.

What litigation posture does this claim set support if challenged via Paragraph IV?

Patent assertion leverage

The patent can be asserted through:
1. composition claims based on dissolution testing,
2. independent PK claim elements if asserted at trial,
3. method-of-use claims using indication-aligned labeling and clinical administration.

Common defense lines

Non-infringement by showing dissolution profile failure in the exact medium/apparatus conditions.
Non-infringement by demonstrating formulated excipient composition does not fall in the solubilizer/medium chain glyceride/solvent weight ranges, or does not provide the required release in the USP Type 2 test.
Invalidity arguments would typically target lack of novelty or obviousness relative to prior celecoxib formulation art, especially fast-release celecoxib systems, but those determinations depend on the referenced prior art and prosecution history not supplied here.

Key claim chart: US 9,949,990 elements and infringement test points

Claim cluster	Required element(s)	Quantitative test points in claim	Highest-risk design target
Claims 1/13/19/25 (composition)	Reduced-dose celecoxib oral composition	Dissolution: ≥70% at 10 min and/or ≥80% at 15 min in 0.01N HCl + 0.5% SLS; USP Type 2 sinkers; 50 rpm; 37°C; 900 mL	Match dissolution kinetics under the same conditions
Claims 2–5 (dose reduction %)	Reduced dose as % less than conventional 400 mg celecoxib capsule	Threshold reductions: ≥20%, ≥40%, ≥55%, ≥70%	Ensure reduction relationship is satisfied
Claims 6–8 / 14–16 / 20–22 / 26–28 (formulation classes)	Solubilizer, medium chain glyceride, solvent in ranges	Solubilizer 10–70% w/w; medium chain glyceride 5–75% w/w; solvent 20–80% w/w	Stay outside at least one weight-range class if feasible
Claims 9 (dosage form)	Solution/suspension/emulsion/liquid mixture	No numeric metrics	Avoid formulation form if the reference product structure differs
Claims 10 (precipitation)	No precipitation in FaSSGF at pH 2.0, 37°C, 50 rpm, 60 min	Precipitation-free at 60 min	Control colloidal stability in simulated gastric conditions
Claims 11/17/23/29 (method)	Administer composition to humans for pain	Indication alignment	Labeling and prescribing evidence
Claims 18/24/30 (PK)	Fasting PK meets one or more AUC/Tlag cutoffs	AUC and Tlag thresholds; Tlag ≤ 8 min	Match early exposure and onset speed

Key Takeaways

US 9,949,990 centers on reduced-dose celecoxib oral compositions that must exhibit fast release in 0.01N HCl + 0.5% SLS using USP Type 2 (sinkers, 50 rpm, 37°C) with explicit acceptance thresholds.
The strongest infringement determinants are the dissolution performance metrics and the formulation class weight ranges for solubilizers, medium chain glycerides, and solvents.
The patent provides multiple enforcement hooks: strength-locked claims (120/180/240 mg), percentage reduction claims, precipitation stability (FaSSGF), broad pain method-of-use, and fasted-state PK cutoffs (including Tlag ≤8 minutes).
For generic or competitor products, the highest entry-risk zone is reduced-dose, fast-release celecoxib formulations that are designed to increase early exposure and dissolution in gastric-like conditions.

FAQs

Which elements are most likely to be disputed in litigation for US 9,949,990?

Dissolution compliance under the exact USP Type 2 conditions and media specified, plus whether the accused formulation falls within the claimed solubilizer/medium chain glyceride/solvent weight ranges.

Can a product avoid infringement if it meets dose reduction but fails dissolution thresholds?

Yes, avoiding the specific dissolution acceptance thresholds targets non-infringement for the composition claims that incorporate those release metrics.

Do the PK claims require matching all AUC values?

No. The claim text requires meeting at least one of the listed AUC/Tlag thresholds.

Do the method-of-use claims depend on any specific indication language?

They depend on treating or ameliorating pain in the broad categories listed; proof typically relies on alignment between labeling/prescribing and administration of the patented composition.

Is a liquid dosage form more exposed under US 9,949,990 than tablets or capsules?

The patent explicitly covers solutions/suspensions/emulsions/liquid mixtures, so liquid formulations designed to meet dissolution and stability metrics are inherently higher risk, though capsules could still infringe if they meet the composition elements.

References (APA)

US Patent 9,949,990 (claims provided by user).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Scilex Pharms	ELYXYB	celecoxib	SOLUTION;ORAL	212157-001	May 5, 2020		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016267685	⤷ Start Trial
Australia	2019203815	⤷ Start Trial
Brazil	112017025445	⤷ Start Trial
Canada	2987272	⤷ Start Trial
China	107847437	⤷ Start Trial
Eurasian Patent Organization	201792530	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,949,990

Which drugs does patent 9,949,990 protect, and when does it expire?

Summary for Patent: 9,949,990